| Literature DB >> 26871474 |
Ying Qi1, Hong Sain Ooi2, Jun Wu3, Jian Chen1, Xiaoli Zhang1, Sheng Tan4, Qing Yu4, Yuan-Yuan Li5,6, Yani Kang1, Hua Li1, Zirui Xiong4, Tao Zhu4, Bingya Liu1,7, Zhifeng Shao1, Xiaodong Zhao1.
Abstract
EZH2, the catalytic component of polycomb repressive complex 2 (PRC2), is frequently overexpressed in human cancers and contributes to tumor initiation and progression, in part through transcriptional silencing of tumor suppressor genes. A number of noncoding RNAs (ncRNAs) recruit EZH2 to specific chromatin loci, where they modulate gene expression. Here, we used RNA immunoprecipitation sequencing (RIP-seq) to profile EZH2-associated transcripts in human gastric cancer cell lines. We identified 8,256 transcripts, including both noncoding and coding transcripts, some of which were derived from cancer-related loci. In particular, we found that long noncoding RNA (lncRNA) MALAT1 binds EZH2, suppresses the tumor suppressor PCDH10, and promotes gastric cellular migration and invasion. Our work thus provides a global view of the EZH2-associated transcriptome and offers new insight into the function of EZH2 in gastric tumorigenesis.Entities:
Keywords: EZH2; MALAT1; RIP-seq; gastric cancer; transcriptional silencing
Mesh:
Substances:
Year: 2016 PMID: 26871474 PMCID: PMC4914315 DOI: 10.18632/oncotarget.7281
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1The modified RIP-seq approach for EZH2-interacting RNA profiling analysis
(A) Schematic representation of modified RIP-seq. (B) RIP-PCR products were analyzed in 2% agarose gel. (C) Native EZH2-RIP RNAs were treated with different kinds of endoribonuclease, followed by RT-qPCR and agarose gel electrophoresis.
Figure 2Characterization of EZH2-associated transcriptome in gastric cancer cells
(A) The scatterplot maps transcripts by their FPKM values in the EZH2-RIP (x axis) and IgG-RIP (y axis). Smoothing was carried out by the function, smoothScatter, in R. Darker shades indicate genes with higher density on the graph. Diagonal dashed line represents the 3:1 EZH2/IgG enrichment threshold. Vertical dashed line represents a cutoff of FPKM [EZH2] = 2. Red, selected transcripts previously suggested to be associated with PRC2. Orange, selected transcripts of known EZH2-associated RNAs but excluded from the EZH2-associated transcriptome in MKN45. (B) Characteristics of the EZH2-associated transcriptome. (C) Composition of the populations of EZH2-associated RNAs expressed at various levels in gastric cancer cells. All genes were ranked by expression level. (D) Correlations between the expression level of RNAs and their enrichment in the EZH2-immunoprecipitated fractions (FC values).
Figure 3Genomic features of EZH2-associated transcriptome
(A) Distinct reads from the EZH2-associated transcriptome were plotted as a function of distance from TSS. (B) Comparison of the binding capacity to EZH2 between protein-coding RNAs and long noncoding RNAs.
Figure 4MALAT1 suppresses PCDH10 by interacting with EZH2 and promotes gastric cancer cellular invasion and migration
(A) ChIP-qPCR assay of the occupancy of EZH2 and H3K27me3 at PCDH10 promoter in MALAT1-knockdown cells. (B) Expression measurement of PCDH10 and EZH2 by RT-qPCR in MALAT1-knockdown cells. (C) Expression measurement of PCDH10 by RT-qPCR in EZH2-knockdown cells. The expression of mRNAs was normalized to GAPDH (means ± SEM, n = 3). (D and E) MALAT1 knockdown (D) and overexpression of PCDH10 (E) inhibit gastric cellular invasion and migration. Images show a representative field. Invasion and migration are expressed as a percentage of controls (means ± S.D., n = 3). Two-tailed Student's t test, *p < 0.05; **p < 0.01. (F) The association between stages III and IV gastric cancer patients’ survival and MALAT1 expression was estimated using the Kaplan–Meier method and the log-rank test (p < 0.01).
Figure 5Schematic representation of the consequence of EZH2-MALAT1 interaction on the gastric cancer migration and invasion
EZH2 is tethered by MALAT1 to PCDH10 locus and promotes gastric cancer metastasis by suppressing PCDH10.